TP53 and neoplasm: This tumor was engineered in vivo with CRISPR/Cas9, and the high baseline p53 expression suggests that a p53 stabilizing point mutation may have been generated via nonhomologous end-joining (NHEJ) repair after CRISPR/Cas9 editing.